Picture of Tarsus Pharmaceuticals logo

TARS — Tarsus Pharmaceuticals News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapFalling Star

Tarsus Pharmaceuticals Inc expected to post a loss of 92 cents a share - Earnings Preview

* Tarsus Pharmaceuticals Inc  TARS.OQ   TARS.O  is expected
to show a rise in quarterly revenue when it reports  results on
August 8 for the period ending June 30 2024
    * The Irvine California-based  company is expected to report
revenue of $31.664 million, according to the mean estimate from
8 analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Tarsus Pharmaceuticals
Inc is
for a loss of 92 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Tarsus
Pharmaceuticals Inc is $61.00​, above​ its last closing price
of $23.14. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -1.21       -1.20      -1.01     Beat    16.2
 Dec. 31 2024              -1.36      -1.31     Beat    3.9
 Jan. 1 0001               -1.37      -1.28     Beat    6.3​
 Jan. 1 0001   -1.06       -1.08      -1.17     Missed  -8.5
 ​​Jan.        -0.92       -0.94      -0.88     Beat    6.9
 1 0001                                                 
 Dec. 31 2022              -0.69      -0.49     Beat    29​
 Sep. 30 2022  -0.88       -0.97      -0.84     Beat    13.7
 Jun. 30 2022  -0.61       -0.59      -0.24     Beat    59.4
 This summary was machine generated August 7 at 01:12 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Tarsus Pharmaceuticals

See all news